Netherlands· NL-fb9fe154f271
Kostaive poeder voor dispersie voor injectie COVID-19 sa-mRNA-vaccin
A covid-19, rna-based vaccine product containing zapomeran, registered in Netherlands by Seqirus Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Covid-19, rna-based vaccine is registered in 11 of 19 countries.
Countries holding a registration under ATC J07BN01 (covid-19, rna-based vaccine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Covid-19, rna-based vaccine · ATC J07BN01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ZAPOMERAN
- Manufacturer
- Seqirus Netherlands B.V.
- Country
- Netherlands (NL)
- ATC code
- J07BN01
- ATC class
- Covid-19, RNA-based vaccine
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/24/1873
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Covid-19, rna-based vaccine in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumKostaiveArcturus Therapeutics Europe
- CzechiaKOSTAIVESeqirus Netherlands B.V., Amsterdam
- FinlandKostaiveSeqirus Netherlands B.V.
- IrelandKostaive powder for dispersion for injection. COVID-19 sa-mRNA VaccineArcturus Therapeutics Europe B.V.
- IcelandKostaiveSeqirus Netherlands B.V.
- PolandKostaiveArcturus Therapeutics Europe B.V.
- SwedenKostaive 5 mikrogram/dos Pulver till injektionsvätska, dispersionSeqirus Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kostaive
- Liechtenstein · Kostaive
- Norway · Kostaive
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9cbdd7e5-887f-4dc1-94ea-6121621ed062 GET /v1/drugs/9cbdd7e5-887f-4dc1-94ea-6121621ed062?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersie voor injectie",
"route": "Intramusculair gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/kostaive-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Covid-19, RNA-based vaccine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131625",
"excipients": [
"1,2-DIMYRISTOYL-RAC-GLYCERO-3-METHOXYPOLYETHYLEENGLYCOL-2000",
"1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE",
"BUTYLHYDROXYTOLUEEN (E 321)",
"CHOLESTEROL",
"KALIUMSORBAAT (E 202)",
"NATRIUMCHLORIDE",
"PENTADECAAN-8-YL 4-(3-(DIMETHYLAMINO)PROPYLSULFANYLCARBONYL-(4-OXO-4-PENTADECAAN-8-YLOXYBUTYL)AMINO)BUTANOAAT",
"POLOXAMEER 188",
"SACCHAROSE",
"TROMETAMOL"
],
"substances": [
"ZAPOMERAN"
],
"leaflet_url": null,
"authorised_at": "2025/02/12",
"procedure_number": "EMEA/H/C/006207",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/24/1873",
"additional_monitoring": "Y"
}See everything about covid-19, rna-based vaccine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.